Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Cabazitaxel in mHRPC
NCT02074137Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jul 2014
- Primary completion
- Mar 2016
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cabazitaxel ginsenoside liposome injection in prostate cancer (PCa), sponsored by Sanofi. Started Jul 2014; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02074137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074137.